While past studies demonstrated decreased renal MMP activity in Type 1 diabetes and in mesangial cells grown under high glucose conditions, renal MMP expression/activity in Type 2 diabetes and the regulation of MMPs by profibrotic factors involved in diabetic renal complications such as endothelin-1 (ET-1) remained unknown.
INTRODUCTION
Approximately 17 million patients suffer from Type 2 diabetes in the United States alone and nephropathy resulting from microvascular complications contributes to the increased morbidity and mortality in diabetes (2) . Both experimental and clinical studies demonstrated that hyperglycemia-induced changes including mesangial and vascular smooth muscle cell growth, basement membrane thickening and as well as extracellular matrix (ECM) deposition, play an important role in the pathophysiology of kidney disease in diabetes (1, 4, 5, 28, 37) . ECM has a rapid turnover due to constant synthesis and degradation of ECM proteins by matrix metalloproteinases (MMP). This rapid synthesis and degradation process is tightly controlled by tissue inhibitors of metalloproteases (TIMPs) (26, 43). The combination of increased ECM protein synthesis, diminished MMP activity and/or increased TIMP activity all could contribute to matrix accumulation in diabetes (15) . Interestingly, recent studies demonstrated that MMPs also contribute to vascular smooth muscle cell (VSMC) growth and migration as well as increased collagen synthesis (11, 33). Hyperglycemia or experimental Type 1 diabetes decreases MMP-2 and membrane type 1 (MT1)-MMP activity in mesangial cells, which has been proposed to lead to mesangium expansion observed in diabetic nephropathy (21, 23, 38, 39). We have shown that vascular expression and activity of MMP-1, MMP-2, MT1-MMP as well as an MMP inducer protein (EMMPRIN) is decreased in diabetic patients (29). However, the early effect of mild hyperglycemia reflective of blood glucose levels observed in patients with Type 2 diabetes on renal MMP expression and activity remains unknown.
Previous studies have shown that endothelin-1 (ET-1) plays an important role in the pathophysiology of diabetic nephropathy (8, 17) . In addition to acting as a vasoconstrictor with subsequent renal hypoperfusion, ET-1 also acts a growth factor causing increased collagen and fibronectin synthesis and deposition in Type 1 diabetes (6). Treatment with a dual ET receptor antagonist bosentan as well as with an ET Aselective antagonist LU 135252 normalized the renal matrix protein expression and prevented the development of proteinuria and renal injury (14). ET-1 inhibits MMP-2 and MT1-MMP expression in mesangial cells (46). Whether ET-1 contributes to increased matrix deposition via stimulation of matrix protein synthesis and/or via the regulation of renal MMP proteins resulting in decreased matrix degradation in Type 2 diabetes has not been studied.
Hypertrophic processes associated with diabetic nephropathy may require the interaction of various growth factors. Recent studies implicated that angiotensin (Ang) II and ET-1, both of which contribute to renal dysfunction, stimulate collagen expression via transactivation of epidermal growth factor receptors (EGFR) (11, 33). To this end the role of ET-1 on renal EGFR transactivation in Type 2 diabetes is yet to be explored.
Connective tissue growth factor (CTGF) has been suggested to be an early predictor of diabetic nephropathy (24, 31, 32). Building on these past studies, we hypothesized that the expression and activity of cortical and medullary MMPs in Goto-Kakizaki (GK) rats, a non-obese and spontaneous model of mild Type 2 diabetes, is altered and treatment with selective ET A receptor antagonist restores diabetes-induced changes in MMP activity. The effect of ET-1 on renal ECM protein expression as well as on potential mediators, EGFR transactivation and CTGF expression, was also studied. Committee of Medical College of Georgia. Male Wistar and GK rats were obtained from Taconic, Inc. (Germantown, NY, USA) at 8 weeks of age. All animals were housed at the Medical College of Georgia's animal care facility, were allowed access to food and water ad libitum, and were maintained on a 12/12 hour light/dark cycle. During housing, drinking water measurements, weight, and blood glucose measurements were performed twice a week. At 12 weeks of age, when all GK animals became diabetic, telemetry transmitters were implanted for blood pressure monitoring as we previously reported (45). After a 2 week-recovery period, control and diabetic animals were placed on the ET A antagonist ABT-627 (5 mg/kg/day) or placebo (9). The drug was dissolved in drinking water at a concentration based on the animal's weight and daily water consumption. Treatment was maintained until the time of sacrifice at 18 weeks of age and blood pressure was monitored by telemetry throughout the treatment period.
RESEARCH DESIGN AND METHODS

Animals
Animals were anesthetized with sodium pentobarbital and exsanguinated via the abdominal aorta. Blood was collected and plasma samples separated immediately were frozen in microcentrifuge tubes containing 0.005% butylated hydroxytoluene (BHT) to prevent oxidation. Kidneys were immediately removed and one kidney was fixed in formalin for morphological studies. Medulla and cortex regions of the second kidney were dissected and frozen separately in liquid nitrogen for MMP activity and immunoblotting experiments. All groups included at least 5 animals per group unless otherwise indicated.
Measurement of metabolic parameters. Blood glucose was measured from the tail vein after 3-4 h fasting using Accucheck glucometer (Roche Diagnostics). Serum cholesterol and triglycerides were determined using colorimetric assay kits (Wako Diagnostics, Richmond, VA). Plasma insulin was assayed with a rat insulin EIA kit from Alpco (Windham, NH). ET-1 levels were measured using an ELISA kit from (American Research Products, Belmont, MA) as we reported previously (10). Urinary microalbumin and creatinine levels were assessed using kits from Exocell, Inc (Philadelphia, PA) and Sigma (St. Louis, MO), respectively. 
Assessment of renal histology and matrix deposition. Kidneys fixed in 10%
formalin were embedded in paraffin, sectioned at 4 micron thickness and mounted on slides, which were then stained with Masson trichrome staining technique to visualise collagen content, which stains blue as opposed to black nuclei and red background.
Images were captured using Axiovert inverted microscope and SPOT software. Cortex or medullary sections were randomly selected and collagen staining intensity was determined qualitatively.
Statistical analysis. A rank transformation was applied to the data prior to analysis to address issues of non-normality (3). A 2x2 analysis of variance was used to investigate the main effects of Disease (control vs. diabetic) and Drug (saline vs. ABT-627) and the interaction between Disease and Drug. Results are given as mean ± SEM. Effects were considered statistically significant at p<0.05. SAS ® version 8.2 was used for all analyses.
RESULTS
Metabolic profile of animals. GK rats developed hyperglycemia around week 12
at the time the telemetry transmitters were implanted and at the end of the study, the blood glucose averaged 168 ± 5 (n=19) vs 108 ± 3 (n=17) mg/dl and treatment with ET A antagonist ABT-627 (n=10 per control or GK) did not have an effect on blood glucose (Table 1) . Plasma insulin levels were significantly lower in the GK group (n=13) than control (n=11) and ABT-627 (n=10/per group) further lowered the plasma insulin in both control and GKs. There was no difference in plasma cholesterol between the groups.
Blood pressure was mildly elevated in the GKs and ABT-627 lowered blood pressure in both control and GKs. Circulating ET-1 levels were higher in diabetic animals (n=13) than in controls (n=20). There was no statistically significant difference in urinary microalbumin (mg/day) levels but creatinine (mg/day) was decreased in the GKs.
Renal MMP expression and activity. MMP2-and -9-dependent gelatinase activity, which has been reported to be down-regulated in diabetes, was assessed by gelatin zymography in the renal cortex and medulla separately. There was very faint MMP-9 activity with no difference between the groups (not shown). Two gelatinolytic bands at 72 and 62 kDa corresponding to proMMP-2 and MMP-2, respectively, were detected in all specimens and total activity corresponding to both of these isoforms were significantly elevated in the medulla and cortex of GK rats as compared to controls (Fig.   1 ). ABT-627 treatment did not have an effect on MMP-2 activity in any of the groups. In order to confirm zymography results, a fluorescence-based gelatinase activity assay that measures total MMP-2 and MMP-9-dependent activity was performed ( Table 2) . A significant increase in gelatinase activity in both cortical and medullary regions in the GKs was observed and ABT-627 treatment failed to decrease gelatinase activity.
To investigate whether the increased MMP activity is associated with changes in protein levels, immunoblotting experiments were performed. As evident from Figure 2A , MMP-2 protein expression was significantly higher in the GKs and ET A antagonism did not have an effect. Although MMP-9 activity was faint in the zymograms, MMP-9 protein was detected in all the groups and it was significantly elevated in the diabetic rats (Fig.   2B ). MT1-MMP, which activates proMMP-2 to MMP-2, was also increased in the medulla of the GKs (Fig. 3A) . In the cortical homogenates, MT1-MMP was increased in both ABT-627-treated controls as well as in untreated GKs (p=0.04). ECM protein fibronectin was significantly higher in the diabetic animals (Fig. 3B) .
Renal EGFR phosphorylation. In order to determine whether and to what extent ET-1 contributes to renal EGFR transactivation in diabetes, native and phosphorylated EGFR levels were determined by immunoblotting. As shown in Fig. 4 , there was no difference in EGFR levels between control and diabetic GK rats in the medulla (p=0.06) but in the cortex EGFR protein was higher in the GK animals (p=0.02). The phosphorylated form of EGFR was significantly higher in the GKs and ABT-627 treatment reduced EGFR phosphorylation in GK rats more than in controls. The ratio of EGFR~P to EGFR was higher (Fig. 4B ). In addition, there was a small but significant increase in Hb-EGF protein levels in the cortex of diabetic rats and ABT-627 treatment prevented this increase (Fig. 4C) . CTGF expression, which is considered an early marker of kidney damage, was assessed in the urine as well as in renal homogenates by immunoblotting. There were low levels of expression in both specimens, which was similar in control and diabetic animals (data not shown).
Renal histology. Kidney sections were stained by Masson trichrome staining to evaluate the kidney structure. There were no apparent morphological changes or collagen accumulation in the GK rats as compared to controls as indicated by blue staining around the glomeruli or tubulointerstitial area (Fig. 5A ). Collagen type I and IV alpha I gene expression was assessed by real-time PCR which demonstrated a 2 and 3-fold increase, respectively, in mRNA levels in the cortex of GK animals as compared to control animals. In ABT-627 treated animals, the expression was similar to control animals, indicating that ET A receptor antagonism prevented this increase in the diabetic rats (Fig. 5B) . 
DISCUSSION
